Comparison · NCT03338920-4158b484
Sumatriptan Nasal Powder vs Placebo: Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Sumatriptan Nasal Powder vs Placebo: Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment. Trial comparisons, record NCT03338920-4158b484. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03338920-4158b484
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.101 | 0.0522 | 0.187 | wilson | |
| Risk in group 2 | 0.113 | 0.0603 | 0.2 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0112 | -0.112 | 0.0894 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.366 | 2.21 | log | |
| Odds ratio, group 1 over group 2 | 0.889 | 0.325 | 2.43 | log | |
| Number needed to treat, for one fewer participant with the outcome on Sumatriptan Nasal Powder than on Placebo | 89 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Sumatriptan Nasal Powder | Participants will be dosed with 22 milligrams (mg) sumatriptan nasal powder via two nosepieces (11 mg per nosepiece).~sumatriptan nasal powder: nasal powder administered via nosepiece | 8 | 79 | OG000 |
| Group 2 | Placebo | Participants will be dosed with matching placebo via nosepieces containing capsules filled with lactose instead of sumatriptan.~Placebo: lactose monohydrate powder administered via nosepiece | 9 | 80 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Who Were Headache Pain Free at 120 Minutes After Treatment
- Description
- Participants will self-report the severity of their headache.
- Time frame
- 120 minutes
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents
- NCT number
- NCT03338920
- Phases
- PHASE3
- Conditions
- Acute Migraine With or Without Aura
- Interventions
- sumatriptan nasal powder, Placebo
- Lead sponsor
- Currax Pharmaceuticals
- Results first posted
- 2023-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03338920?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03338920-4158b484